Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Infection with Histoplasma capsulatum in 58 patients whose immune responses were suppressed (Immunosuppressed patients) (16 from the present series and 42 described previously) was analyzed. The most common underlying diseases were Hodgkin's disease (29 per cent), chronic lymphocytic leukemia (19 per cent) and acute lymphocytic leukemia (17 per cent). Sixty-three per cent of the patients had received cytotoxic drugs, and 57 per cent had taken corticosteroids. Widely disseminated infection occurred in 88 per cent of the patients, with predominant involvement of lungs and organs of the reticuloendothelial system. Localized pulmonary infection was present in the remaining patients. The most useful diagnostic method was bone marrow biopsy with microscopic examination for the intracellular yeast form of H. capsulatum. Biopsy of oral lesions, lung, liver and lymph node also proved diagnostically helpful. Growth of H. capsulatum in culture was frequently too slow to be beneficial in diagnosing histoplasmosis in ill patients. Serologic methods were of little diagnostic help in this population of immunosuppressed patients. The response to amphotericin B therapy was excellent (6.7 per cent mortality rate) in those patients in whom the diagnosis was established early and in whom a full course of antifungal therapy could be given. In contrast, the mortality rate in patients who received no antifungal therapy or less than 1 g of amphotericin B was 100 per cent.
 ...
PMID:Histoplasmosis in immunosuppressed patients. 35 45

The development of either histiocytic lymphoma or Hodgkin disease in association with pre-existing chronic lymphocytic leukemia has been described in the literature as a terminal event. We describe two patients in whom the diagnosis of a second malignant lymphoma was made during life and who achieved objective clinical response after a change in therapy to a more aggressive combination of drugs. We conclude that patients with chronic lymphocytic leukemia who have had a sudden change in their clinical course should have thorough reevaluation, looking specifically for the development of a second lymphoproliferative disorder. If this is discovered, more aggressive therapy should be initiated.
 ...
PMID:Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases. 38 74

Serum IgE concentrations were determined and IgE turnover studies were performed in control individuals as well as in patients with several disease states. Patients with common variable hypogammaglobulinemia, thymoma and hypogammaglobulinemia, ataxia telangiectasia, and selective IgA deficiency had significantly decreased mean serum IgE concentrations. In turnover studies, this was found to be due to decreased IgE synthesis. In spite of these depressed mean values, some patients with common variable hypogammaglobulinemia had normal serum IgE concentrations and synthetic rates. Patients with the Wiskott-Aldrich syndrome had a significantly elevated mean serum IgE concentration. In one of four patients studied with the turnover technique, a strikingly high IgE concentration was present and was associated with an elevated IgE synthetic rate. Three other patients had both normal serum IgE concentrations and synthetic rates. Patients with chronic lymphocytic leukemia had significantly decreased mean serum concentrations and synthetic rates for IgE. The depressed IgE synthesis was associated with a significantly prolonged IgE half-life. Patients with Hodgkin's disease had significantly increased serum IgE concentrations. One of three patients studied had a high serum IgE concentration and synthetic rate of IgE. The two other patients had normal serum IgE concentrations associated with normal synthetic rates. Finally patients with protein-losing enteropathy or familial hypercatabolic hypoproteinemia had normal IgE concentrations associated with normal IgE metabolic parameters. In these cases, the disorder in the catabolic rate was not severe enough to affect the total amount of circulating IgE because IgE normally has a very high fractional catabolic rate. In general, IgE levels in a variety of disease states were correlated with IgE synthetic rates and abnormalities in the catabolic rate of IgE in disease did not exert an important effect on IgE concentration.
 ...
PMID:The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions. 40 20

We have studied the thrombocytopenia of lymphoproliferative disorders using a measurement of membrane-bound IgG by an antiglobulin consumption assay. Nine patients with chronic lymphocytic leukemia (CLL) and thrombocytopenia had increased membrane-bound IgG. Two patients with non-Hodgkins lymphoma and 1 patient with Hodgkins disease also had thrombocytopenia and increased membrane-bound IgG. Five of the patients with CLL had positive direct antiglobulin (Coombs) tests on red cells; of these, 3 patients had hemolytic anemia. In eight of the 9 patients with CLL, thrombocytopenia, and increased platelet-bound-IgG, the platelet count increased with the administration of prednisone or an alkylating agent, with splenectomy, or with a combination of these.
 ...
PMID:Immune thrombocytopenia in lymphoproliferative diseases. 42 6

Fourty-three of 61 patients suffering from low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification were subjected to an intermittent combination chemotherapy with chlorambucil and prednisone. In 12 of 35 evaluable patients a complete remission, in 14 of 35 a partial remission could be achieved. The mean remission time of patients with a complete remission exceeds 16 months, that of patients with a partial remission amounts to more than 8 months. In 9 of 35 cases a remission could not be achieved. As 10 of the 12 patients in whom a complete remission could be obtained are alive, the median survival time in cases of complete remission cannot yet be determined. The hematological toxicity was very low, nausea and lack of appetite were observed in 9 of 35 patients. Three of 35 treated and evaluable patients died, viz., 1 patient with a centroblastic-centrocytic lymphoma and 1 patient with a chronic lymphocytic leukemia died from the sequelae of progression during the chemotherapy of second choice according to the COP regimen. The third patient with a centroblastic-centrocytic lymphoma died from the sequelae of an intrahepatic cholestatic icterus, also during the chemotherapy of second choice according to the COP regimen. In the last-mentioned case, autopsy also confirmed a continuous complete remission of the centroblastic-centrocytic lymphoma.
 ...
PMID:Intermittent combination chemotherapy with chlorambucil and prednisone of low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification. 43 82

Total hemolytic complement (CH50) and eight antigenic fractions of the complement system were determined in 30 patients with hematological neoplasias, distributed into the following groups: six cases of non-Hodgkin's lymphomas (NHL), seven cases of chronic lymphocytic leukemia (CLL), five cases of Hodgkin's disease (HD), seven cases of acute leukemia (AL), three cases of chronic myeloid leukemia (CML) and two cases of multiple myeloma (MM). CH50 was titred accordingly to a modification of the Kabat and Mayer method, C1q, C1s, C3, C4, C5, INHC1, C3A and properdin were determined with specific antisera by Manani and Laurell's techniques. The results obtained showed significant increase in CH50 above normal values in patients with HD, AL, and CML, especially the former, even in early stages. C1s was found to be increased in CML and AL, as well as C3 in CML. C4 is increased in CML and HD. C5 follows a course similar to C4, being also increased CLL and MM. C9 is increased in all groups, except NHL. A significant increase in C3A was found in NHL, HD and AL. There were no significant variations in C1s, INHC1 and properdin in any of the former groups. No correlation was found between clinical course and complement increase. The role of complement in neoplastic disease is discussed.
 ...
PMID:Complement in hematological neoplasias. 47 24

Whereas the contribution of exploratory laparotomy in Hodgkin's disease is well characterized, its value in Non-Hodgkin lymphoma (NHL) is not yet defined. This retrospective analysis of 31 cases is a contribution to the ongoing discussion. Laparotomy/splenectomy (LS) was done in 17 patients for diagnostic reasons and in 14 with therapeutic intent. Perioperative morbidity was low. In 17 cases the NHL had infiltrated the spleen. Indications for therapeutic LS were hemolytic anemia, pancytopenia and excessive lymphocytosis with granulocytopenia. The therapeutic benefit from splenectomy was satisfactory, especially in patients with well-differentiated lymphocytic leukemia of type CLL. In contrast, the diagnostic value of LS was minimal, except in patients with first diagnosis of NHL through LS. There was no change in tumor stage in any case. However, 4 false-negative findings contrast with the rapidly adverse course in these patients. Routine LS in patients with NHL does not appear to be justified, but has its value in NHL with primary abdominal localization. Therapeutic splenectomy is of benefit for the majority of patients, particularly those with CLL.
 ...
PMID:[Diagnostic and therapeutic importance of splenectomy in patients with non-Hodgkin's lymphoma]. 48 11

Issuing from the clinico-prognostic importance of the classification after Kiel of the malignant non-Hodgkin-lymphomas the results of the attempt of a reclassification of positive bioptic findings of the iliac crest judged according to the former German nomenclature are described and discussed after the Kiel classification. In the total material of 725 biopsies 76 positive findings of the marrow were stated in malignant non-Hodgkin-lymphomas, which at 67.1% consist of such with a lower and at 32.9% of such with a high degree of malignity, in which case a strong decrease of the formerly diagnosed CLL is to be seen after reclassification, whereas the immunocytomas render the by far largest proportion. The former malignant reticuloses disappear per definitionem after reclassification and, as it was expected, are broadly distributed. In 112 biopsies which were performed on account of the suspicion of an affection of the marrow in malignant non-Hodgkin-lymphomas the 76 positive findings correspond to a frequency of 67.9%, which, however, must critically be judged, since the case in question are very selected numbers of patients.
 ...
PMID:[Iliac crest biopsy findings in malignant non-Hodgkin lymphoma]. 53 69

149 patients with non Hodgkin lymphomas (NHL) were observed at the III. Medical Department of the Hanusch Hospital during 1972--1978. 15 out of 106 patients with low malignant NHL had autoimmune hemolytic anemia (AHA). None of the patients with high malignant NHL showed evidence of hemolysis. In 10 cases AHA was diagnosed together with the lymphoproliferative disease. In 4 cases diagnosis of AHA and NHL was established at the same time and in only 1 patient diagnosis of AHA preceded the lymphatic disease. All patients had distinct signs of hemolysis with moderate to severe anemia. 4 patients with immunocytic lymphomas had IgM paraproteins and an elevation of gamma-globulins, all other patients had mild to severe hypogammaglobulinemia. Therapy in all cases consisted of corticosteroids and cytostatics (Chlorambucil, Cyclophosphamide). In none of our cases splenectomy was performed. AHA seems to be a bad prognostic factor in patients with chronic lymphocytic leukemia. Survival time in patients with chronic lymphocytic leukemia and AHA was 18 months shorter than in all other patients suffering from chronic lymphocytic leukemia.
 ...
PMID:[Accompanying hemolysis in lymphoproliferative diseases]. 55 12

Serum of 70 patients with malignant lymphoma was tested for concentration of ferritin by immunoradiometric assay. Serum of patients with Hodgkin's disease showed an apparently increased ferritin concentration only in the stage III and IV. Concentration of serum ferritin was found normal in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma of low malignancy. Among patients with non-Hodgkin's lymphome of high malignancy only one who suffered from advanced immunoblastic sarcoma showed increased concentration of serum ferritin. Patients with elevated concentration of serum ferritin had a decreased level of serum iron and showed also anemia. Their bone marrow reticulum was rich in dyeing iron. These results suggest that hyperferritinemia in patients with advanced Hodgkin's disease is related to a lack of release of iron from reticuloendothelial system.
 ...
PMID:[Serumferritin in patients with malignant lymphomas (author's transl)]. 59 80


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>